KYORIN Co., Ltd. announces that its wholly owned subsidiary of KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Tokyo, President: Keiji Hirai, Ph.D.) today signed a License Agreement with Senju Pharmaceutical Co., Ltd. ("Senju") (Head office: Osaka, President: Yukoh Yoshida), concerning the grant of an exclusive marketing right to Senju on Gatifloxacin ophthalmic solution for China. Gatifloxacin is a broad spectrum synthetic antibacterial agent originated by Kyorin.

Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China